

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 25 MAY 2023;
(2) CHANGE OF DIRECTORS
AND
COMPOSITION OF BOARD COMMITTEES;
AND
(3) CHANGE OF SUPERVISOR**

POLL RESULTS OF THE AGM

The Board is pleased to announce that all resolutions as set out in the Notice dated 6 April 2023 and the Supplemental Notice dated 10 May 2023 were duly passed by way of poll by the Shareholders at the AGM held on Thursday, 25 May 2023.

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The Board also announces that as the appointment of Mr. Lin Yanglin, Ms. Cheng Yali and Dr. Zheng Yongtang as the Directors expired at the AGM and all of them did not offer themselves for re-appointment as they would like to devote more time on their other commitments, (a) Mr. Lin ceased to be an executive Director; (b) Ms. Cheng ceased to be a non-executive Director; and (c) Dr. Zheng ceased to be an independent non-executive Director, the chairman of each of the Audit Committee and the Remuneration Committee and a member of the Nomination Committee, all with effect from 25 May 2023.

The Board further announces that Mr. Chen Peng has been appointed as an executive Director, each of Mr. Chen Zhengyong, Mr. Li Zhonghua and Dr. Gao Guangxia has been appointed as a non-executive Director and Prof. Shen Zuojun has been appointed as an independent non-executive Director, all with effect from 25 May 2023 following the approval of their respective appointments by the Shareholders at the AGM.

The Board further announces that following the appointment of Prof. Shen Zuojun as an independent non-executive Director, he has also been appointed as the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee with effect from 25 May 2023. Mr. Lu Qi has been appointed as the chairman of the Audit Committee with effect from 25 May 2023.

CHANGE OF SUPERVISOR

The Board further announces that as the appointment of Mr. Zhou Jie as a Supervisor expired at the AGM and he did not offer himself for re-appointment as he would like to devote more time on his other commitments, Mr. Zhou has ceased to be a Supervisor with effect from 25 May 2023.

The Board further announces that (i) Mr. Li Jifeng has been appointed as a Supervisor with effect from 25 May 2023 following the approval of his appointment by the Shareholders at the AGM and (ii) Ms. Ren Junhe has been re-elected by the employees of the Company as a Supervisor pursuant to Article 119 of the Articles of Association with effect from 25 May 2023.

References are made to the notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) dated 6 April 2023 and the supplemental notice (the “**Supplemental Notice**”) of the AGM dated 10 May 2023 of Biosino Bio-Technology and Science Incorporation (the “**Company**”), and the circular (the “**Circular**”) of the Company dated 4 May 2023 and the supplemental circular (the “**Supplemental Circular**”) of the Company dated 10 May 2023. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular and the Supplemental Circular (as the case may be).

POLL RESULTS OF THE AGM

The AGM was held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Thursday, 25 May 2023. The Board is pleased to announce that all resolutions as set out in the Notice and the Supplemental Notice were duly passed at the AGM. As at the date of the AGM, the Company issued a total of 144,707,176 Shares, comprising 64,286,143 H Shares and 80,421,033 Domestic Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM. There were no Shares entitling the holders thereof to attend and vote only against the resolutions at the AGM. No restriction was imposed on any Shareholder casting votes on any of the proposed resolutions at the AGM. All the resolutions at the AGM were put to the vote by way of poll. BDO China Shu Lun Pan Certified Public Accountants LLP was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results of the respective resolutions at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To consider and approve the report of the Board for the year ended 31 December 2022;	106,217,000 (100%)**	0 (0%)**
2.	To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2022;	106,217,000 (100%)**	0 (0%)**
3.	To consider and approve the audited consolidated financial statements of the Company and its subsidiaries and the independent auditors' report for the year ended 31 December 2022;	106,217,000 (100%)**	0 (0%)**
4.	To consider and approve the 2022 annual final financial report and the 2023 financial budget report of the Company;	106,217,000 (100%)**	0 (0%)**
5.	To consider and approve the re-appointment of Ernst & Young Hua Ming as the PRC auditors and Ernst & Young as the international auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration;	106,217,000 (100%)**	0 (0%)**

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
5A.	To consider and approve the appointment and re-appointments of the following Directors, and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:–		
	(a) To consider and approve the re-appointment of Mr. Wu Lebin as an executive Director;	106,067,000 (100%)**	0 (0%)**
	(b) To consider and approve the re-appointment of Dr. Sun Zhe as a non-executive Director;	106,067,000 (100%)**	0 (0%)**
	(c) To consider and approve the re-appointment of Mr. Lu Qi as an independent non-executive Director;	106,067,000 (100%)**	0 (0%)**
	(d) To consider and approve the re-appointment of Prof. Shen Jiangang as an independent non-executive Director;	106,067,000 (100%)**	0 (0%)**
	(e) To consider and approve the appointment of Mr. Chen Peng as an executive Director;	94,736,666 (100%)**	0 (0%)**
	(f) To consider and approve the appointment of Mr. Chen Zhengyong as a non-executive Director;	106,067,000 (100%)**	0 (0%)**
	(g) To consider and approve the appointment of Mr. Li Zhonghua as a non-executive Director;	88,347,686 (100%)**	0 (0%)**
	(h) To consider and approve the appointment of Dr. Gao Guangxia as a non-executive Director; and	106,067,000 (100%)**	0 (0%)**
	(i) To consider and approve the appointment of Prof. Shen Zuojun as an independent non-executive Director.	106,067,000 (100%)**	0 (0%)**

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
5B.	To consider and approve the appointment and re-appointment of the following Supervisors and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:–		
	(a) To consider and approve the re-appointment of Dr. Shen Sheng as a Supervisor; and	106,217,000 (100%)**	0 (0%)**
	(b) To consider and approve the appointment of Mr. Li Jifeng as a Supervisor.	106,217,000 (100%)**	0 (0%)**
SPECIAL RESOLUTIONS			
6.	To give a general mandate to the Board to issue, allot and deal with additional Shares not exceeding 20% of the Shares in issue.	74,908,424 (70.52%)**	31,308,576 (29.48%)**
7.	To consider and approve the proposed amendments to the Articles of Association.	106,217,000 (100%)**	0 (0%)**

** *The percentage of voting Shares is based on the total number of Shares held by the Shareholders who voted at the AGM in person or by proxy.*

As more than 50% of the total number of Shares held by the Shareholders who voted at the AGM were cast in favour of each of the resolution nos. (1) to (5B) and more than two-thirds of the total number of Shares held by the Shareholders who voted at the AGM were cast in favour of resolution nos. (6) and (7), all the above resolutions were approved by the Shareholders.

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The Board also announces that as the appointment of Mr. Lin Yanglin (“**Mr. Lin**”), Ms. Cheng Yali (“**Ms. Cheng**”) and Dr. Zheng Yongtang (“**Dr. Zheng**”) as the Directors expired at the AGM and all of them did not offer themselves for re-appointment as they would like to devote more time on their other commitments, (a) Mr. Lin ceased to be an executive Director; (b) Ms. Cheng ceased to be a non-executive Director; and (c) Dr. Zheng ceased to be an independent non-executive Director, the chairman of each of the audit committee (the “**Audit Committee**”) and the remuneration committee (the “**Remuneration Committee**”) and a member of the nomination committee (the “**Nomination Committee**”) of the Company, all with effect from 25 May 2023.

Each of Mr. Lin, Ms. Cheng and Dr. Zheng has confirmed that he/she has no disagreement with the Board, and there are no matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its appreciation for the valuable contribution of Mr. Lin, Ms. Cheng and Dr. Zheng towards the Company during their tenure of service.

The Board further announces that Mr. Chen Peng has been appointed as an executive Director, each of Mr. Chen Zhengyong, Mr. Li Zhonghua and Dr. Gao Guangxia has been appointed as a non-executive Director and Prof. Shen Zuojun has been appointed as an independent non-executive Director, all with effect from 25 May 2023 following the approval of their respective appointments by the Shareholders at the AGM.

Following the appointment of Prof. Shen Zuojun as an independent non-executive Director, he has also been appointed as the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee with effect from 25 May 2023. Mr. Lu Qi has been appointed as the chairman of the Audit Committee with effect from 25 May 2023.

Biographical details of Mr. Chen Peng, Mr. Chen Zhengyong, Mr. Li Zhonghua, Dr. Gao Guangxia and Prof. Shen Zuojun are as follows:

Mr. CHEN Peng (陳鵬先生), aged 49, was appointed as the president of the Company on 7 December 2021. He graduated from Anhui University of Chinese Medicine (安徽中醫學院) with a bachelor's degree in Integrated Chinese and Western Medicine (中西醫結合臨床專業) in 1998. He served as the technical director of Shanghai Fosun High-tech (Group) Co., Ltd.* (上海複星高科技(集團)公司), a director of Anhui Guoke Kangyi Medical Technology Co., Ltd.* (安徽國科康儀醫療科技有限公司) and Hefei Guoke Kangyi Medical Laboratory Co., Ltd.* (合肥國科康儀醫學檢驗實驗室有限公司), the chairman and president of Hefei Anhui Meikang Hospital Investment Management Co., Ltd. (合肥安徽美康醫院投資管理股份有限公司), the general manager of Guoke Health Hospital Industry (Hefei) Co., Ltd.* (國科健康醫院產業(合肥)有限公司), the chairman of Guoke Health Information Technology (Anhui) Co., Ltd. (國科健康信息科技(安徽)有限公司) and the chairman of Step Stone (Suzhou) Biotechnology Co., Ltd. (踏石(蘇州)生物技術有限公司). He joined the Company in December 2021.

The Company will enter into a service agreement with Mr. Chen Peng and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen Peng does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications.

As at the date of this announcement, Jingning Guoke Kangyi Enterprise Management Center LLP* (景寧國科康儀企業管理中心(有限合夥)) (“**Jingning**”) owned 11,330,334 Domestic Shares and Mr. Chen Peng owns 99.5% of equity interests in Jingning. Accordingly, he is deemed to be interested in the 11,330,334 Domestic Shares owned by Jingning. Other than disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, other than being the father of Ms. Chen Chen (陳晨), a substantial Shareholder, Mr. Chen Peng does not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

There are no other matters relating to the appointment of Mr. Chen Peng that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Mr. CHEN Zhengyong (陳正永先生), aged 60, has over 40 years of experience in the PRC medical testing and in vitro diagnostic industry. From 1983 to 1993, he was employed at Chengdu Tenth Hospital* (成都市第十醫院) where he was responsible for diagnostic testing. Since 1994, he has been engaged in the business of precision medicine and in vitro diagnostic. He has served as the chairman of the board of a number of companies including Sichuan Zhong Sheng Medical Devices Co., Ltd.* (四川中生醫療器械有限責任公司) since 2012, Sichuan Century Tongchang Health Management Co., Ltd.* (四川世紀同昌健康管理有限責任公司) since 2015 and Chengdu Tongchang Medical Laboratory Co., Ltd.* (成都同昌醫學檢驗所有限公司) since 2017.

Mr. Chen Zhengyong obtained his diploma from Chongqing Medical and Pharmaceutical College (重慶醫藥高等專科學校) in clinical laboratory (檢驗專業) in 1983. He studied Chinese language and literature (漢語言文學專業) at Sichuan Broadcast Television University* (四川省廣播電視大學) (currently known as Sichuan Open University (四川開放大學)) from 1985 to 1988, studied Master of Business Administration at Sichuan University of Finance and Economics (四川財經大學) from 2014 to 2016 and studied Master of Business Administration at Peking University (北京大學) from 2018 to 2020.

The Company will enter into a service agreement with him and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen Zhengyong does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications.

As at the date of this announcement, Sichuan Zhongsheng Medical Instrument Co., Ltd. (“**Sichuan Zhongsheng**”) owned 10,000,000 Domestic Shares. As the equity interests of Sichuan Zhongsheng were owned as to 75.35% by Mr. Chen Zhengyong, he is deemed to be interested in the Domestic Shares owned by Sichuan Zhongsheng pursuant to the SFO. Accordingly, he is deemed to be interested in the 10,000,000 Domestic Shares owned by Jingning. Other than disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, other than being the father of Ms. Chen Zhaoyang (陳昭陽), a substantial Shareholder, Mr. Chen Zhengyong did not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

There are no other matters relating to the appointment of Mr. Chen Zhengyong that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Mr. LI Zhonghua (李忠華先生), aged 60, has experience working as a supervisor teach in medical diagnostic profession, a secretary and deputy secretary of the Youth League Committee (團委書記及副書記), a clinical laboratory doctor at the hospital. Currently, Mr. Li serves as the deputy director of the Pharmaceutical Professional Committee* of the Yunnan Provincial Party Committee of the Peasants and Workers Democratic Party* (農工民主黨雲南省委藥物專業委員會副主任). From 1993 to December 1997, Mr. Li worked at Shanghai Kehua Biotechnology Co., Ltd.* (上海科華生物科技股份有限公司工作). In 1998, Mr. Li commenced his own business and was a senior management personnel that inspects medical equipment products in Yunnan Province. Mr. Li founded Kunming Huasheng Technology Co., Ltd.* (昆明華聖科技有限公司) and Yunnan Guoke Kangyi Biotechnology Co., Ltd.* (雲南國科康儀生物科技股份有限公司). Mr. Li was a graduate student at Kunming Medical University (昆明醫科大學) (previously known as Kunming Medical College (昆明醫學院)) and obtained his EMBA degree from Peking University HSBC Business School.

The Company will enter into a service agreement with Mr. Li and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Li does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. Mr. Li does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, other than being the father of Mr. Li Yangyixiong, a substantial Shareholder, Mr. Li did not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

There are no other matters relating to the appointment of Mr. Li that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Dr. GAO Guangxia (高光俠博士), aged 58, joined the Company in January 2007 and acted as a non-executive director and the vice chairman of the Company between January 2007 and October 2014. He is currently as a research scientist at the IBP of Chinese Academy of Sciences, a director of the main laboratory of infection and immunity at Chinese Academy of Sciences, the legal representative of Beijing Pusai Funds Management Co., Ltd. He was previously the deputy director of the IBP of Chinese Academy of Sciences.

Dr. Gao obtained his bachelor's degree with a major in biochemistry from Peking University in 1988 and his doctorate degree from the department of biochemistry of Columbia University, the United States in 1995. He was a postdoctoral fellow at the Howard Hughes Medical Institute of Columbia University, the United States from 1995 to 1999 and was appointed as an associate research scientist in the Department of Biochemistry of Columbia University, the United States from 1999 to 2001. Since 2001, he has participated as a researcher in the One Hundred Talent Project (百人計劃) of Chinese Academy of Sciences. He received sponsorship from the National Outstanding Youth Fund (國家傑出青年基金) in 2002.

The Company will enter into a service agreement with him and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the date of this announcement, Dr. Gao did not hold any directorship in other public listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO.

There is no other information which is discloseable, nor is/was Dr. Gao involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the re-appointment of Dr. Gao as a non-executive Director that needs to be brought to the attention of the Shareholders.

Prof. SHEN Zuojun (沈佐君教授), aged 60, currently holds a number of positions including being an associate professor, a supervisor to doctorate degree students and a supervisor diagnostician (一級主任檢驗師) at the First Affiliated Hospital of the University of Science and Technology of China (中國科學技術大學附屬第一醫院) (also known as Anhui Provincial Hospital (安徽省立醫院)). In 1998, he obtained his doctorate degree in medicine (醫學博士學位) from China Union Medical College (中國協和醫科大學). From 1998 to 2000, he was a post-doctoral fellow (博士後) at Harvard Medical School in the United States.

In 2017, Prof. Shen Zuojun was awarded as one of the 8th “National Health and Family Planning Outstanding Contribution for the Youth and Middle Aged Experts (國家衛生計生突出貢獻中青年專家)” and in 2018, he obtained special allowance from the State Council. He is currently a national member of the Clinical Laboratory Professional Committee (臨床檢驗專業委員會) of the Chinese Hospital Management Society* (中華醫院管理學會), a national member of the Health Professional Qualification Examination Expert Committee (衛生專業技術資格考試專家委員會), a member of the American Association for Clinical Chemistry (美國臨床化學會), and an editorial member of Chinese Journal of Laboratory Medicine* (中華檢驗醫學雜誌), Journal of Clinical Blood Transfusion and Laboratory* (臨床輸血與檢驗雜誌), Journal of Clinical Laboratory* (臨床檢驗雜誌).

Prof. Shen Zuojun will enter into a service agreement with the Company upon his appointment as an independent non-executive Director is approved by the Shareholders at the AGM. His term of service with the Company will take effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Prof. Shen Zuojun does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. He does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). He does not have any relationship with other Directors, senior management, substantial or controlling Shareholders as defined in the GEM Listing Rules.

Save as disclosed above, Prof. Shen Zuojun has met the independent criteria set out in Rule 5.09 of the GEM Listing Rules and there are no other matters relating to the appointment of him that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

The Board wishes to take this opportunity to welcome the newly appointed Directors for joining the Board.

CHANGE OF SUPERVISOR

The Board further announces that as the appointment of Mr. Zhou Jie (“**Mr. Zhou**”) as a Supervisor expired at the AGM and he did not offer himself for re-appointment as he would like to devote more time on his other commitments, Mr. Zhou ceased to be a Supervisor with effect from 25 May 2023.

Mr. Zhou has confirmed that he has no disagreement with the Board, and there are no matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its appreciation for the valuable contribution of Mr. Zhou towards the Company during his tenure of service.

The Board further announces that (i) Mr. Li Jifeng (“**Mr. Li**”) has been appointed as a Supervisor with effect from 25 May 2023 following the approval of his appointment by the Shareholders at the AGM and (ii) Ms. Ren Junhe has been re-elected by the employees of the Company as a Supervisor pursuant to Article 119 of the Articles of Association with effect from 25 May 2023.

Biographical details of Mr. Li are as follows:

Mr. LI Jifeng (李繼峰先生), aged 44, served at the 69243 Army Hospital from 1994 to 2006. From 1999 to August 2006, he successively studied in the Laboratory Department, Ultrasound Department, and Physiotherapy Department of the General Hospital of the Military Region. From December 2006 to April 2016, he successively worked at Xinjiang Haokang Co., Ltd.* (新疆昊康公司), Sichuan Mike Co., Ltd.* (四川邁克公司), Japan Sysmex Co., Ltd.* (日本希森美康公司), Shanghai Pinluo Investment Co., Ltd.* (上海品羅投資有限公司) where he served as an application engineer, sales manager, regional director, and IVD investment consultant respectively. Furthermore, Mr. Li founded Xinjiang Senyu Huikang Co., Ltd.* (新疆森宇惠康公司) in November 2016, and Xinjiang Guoke Kangyi Co., Ltd.* (新疆國科康儀公司) in December 2017. He possesses 10 years of working experience at hospitals and 16 years in the medical industry. He obtained his bachelor’s degree in medical testing (supervising examiner) (醫學檢驗(主管檢驗師)) from Shihezi University (石河子大學) in 2014.

Mr. Li Jifeng will enter into a service agreement with the Company upon his appointment as a Supervisor is approved by the Shareholders at the AGM. His term of service with the Company will take effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the supervisory committee. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the date of this announcement, Mr. Li did not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO. There is no other information which is discloseable, nor is/was he involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed appointment of Mr. Li as a Supervisor that needs to be brought to the attention of the Shareholders.

The Board wishes to take this opportunity to welcome Mr. Li for joining the Company.

* *For identification purpose only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the PRC, 25 May 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Dr. Sun Zhe (孫哲博士)

Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生)

Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangang (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.